Cite
Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity.
MLA
Nawaf, Maher G., et al. “Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade While Preserving Excellent Anti-CD8 Tumor Immunity.” Journal of Immunology, vol. 199, no. 3, Aug. 2017, pp. 974–81. EBSCOhost, https://doi.org/10.4049/jimmunol.1700088.
APA
Nawaf, M. G., Ulvmar, M. H., Withers, D. R., McConnell, F. M., Gaspal, F. M., Webb, G. J., Jones, N. D., Hideo Yagita, Allison, J. P., & Lane, P. J. L. (2017). Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity. Journal of Immunology, 199(3), 974–981. https://doi.org/10.4049/jimmunol.1700088
Chicago
Nawaf, Maher G., Maria H. Ulvmar, David R. Withers, Fiona M. McConnell, Fabrina M. Gaspal, Gwilym J. Webb, Nick D. Jones, Hideo Yagita, James P. Allison, and Peter J. L. Lane. 2017. “Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade While Preserving Excellent Anti-CD8 Tumor Immunity.” Journal of Immunology 199 (3): 974–81. doi:10.4049/jimmunol.1700088.